title: Targeted signal transduction therapies in myeloid malignancies.
abstract: The myeloid malignancies include the myeloproliferative neoplasms (MPN) including chronic myeloid leukemia (CML), and acute myeloid leukemia (AML). A growing body of evidence documents that these diseases are caused by genetic mutations that constitutively activate tyrosine kinases. They include the BCR/ABL in CML, the V617F JAK2 in Philadelphia chromosome-negative MPN, and the Flt3 ITD and TKD mutations in AML. Trials of the ABL kinase inhibitor, imatinib, have revolutionized the treatment of CML, and there are ongoing studies with other kinase inhibitors in MPN and AML. Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively. It is becoming apparent that although these kinase mutations have similar effects in vitro, each of the diseases has unique features that alter the use of kinase inhibitors in the clinic.
authors.affiliation: University of Pennsylvania, Philadelphia, 19104, USA.
authors.forename: Emma
authors.initials: E
authors.lastname: Scott
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Hexner
authors.forename: Alexander
authors.initials: A
authors.lastname: Perl
authors.forename: Martin
authors.initials: M
authors.lastname: Carroll
mesh_terms: D002986:Clinical Trials as Topic; D017326:Clinical Trials, Phase III as Topic; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000235:genetics; D005260:Female; D006801:Humans; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors* / Q000235:genetics; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D008297:Male; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000138:chemical synthesis; D016032:Randomized Controlled Trials as Topic; D015398:Signal Transduction / Q000187:drug effects* / Q000235:genetics; D051941:fms-Like Tyrosine Kinase 3 / Q000037:antagonists & inhibitors* / Q000235:genetics
chemical_list: D047428:Protein Kinase Inhibitors; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3; D053614:Janus Kinase 2
references.citation: Blood. 2010 Feb 11;115(6):1131-6
references.pmid: 20008298
references.citation: Lancet. 2005 Mar 19-25;365(9464):1054-61
references.pmid: 15781101
references.citation: N Engl J Med. 2006 Dec 7;355(23):2408-17
references.pmid: 17151364
references.citation: Science. 2004 Jul 16;305(5682):399-401
references.pmid: 15256671
references.citation: Blood. 2001 Sep 15;98(6):1752-9
references.pmid: 11535508
references.citation: Blood. 2004 May 15;103(10):3669-76
references.pmid: 14726387
references.citation: Blood. 2001 Apr 15;97(8):2434-9
references.pmid: 11290608
references.citation: N Engl J Med. 2008 May 1;358(18):1909-18
references.pmid: 18450602
references.citation: J Clin Oncol. 2006 Aug 20;24(24):3887-94
references.pmid: 16864856
references.citation: N Engl J Med. 2010 Jun 17;362(24):2251-9
references.pmid: 20525993
references.citation: N Engl J Med. 2010 Jun 17;362(24):2260-70
references.pmid: 20525995
references.citation: Leukemia. 2007 Aug;21(8):1658-68
references.pmid: 17541402
references.citation: Blood. 2010 Apr 15;115(15):3109-17
references.pmid: 20130243
references.citation: Leukemia. 2008 Jun;22(6):1200-6
references.pmid: 18401416
references.citation: Nature. 2005 Apr 28;434(7037):1144-8
references.pmid: 15793561
references.citation: Blood. 2001 Sep 1;98(5):1302-11
references.pmid: 11520775
references.citation: Blood. 2008 Jun 15;111(12):5663-71
references.pmid: 17984313
references.citation: Cancer Cell. 2005 Feb;7(2):129-41
references.pmid: 15710326
references.citation: J Clin Oncol. 2010 Apr 10;28(11):1856-62
references.pmid: 20212254
references.citation: Blood. 2009 Apr 23;113(17):3938-46
references.pmid: 19029442
references.citation: Leukemia. 2003 Sep;17(9):1738-52
references.pmid: 12970773
references.citation: Cancer Cell. 2005 Apr;7(4):387-97
references.pmid: 15837627
references.citation: Mol Cell. 2004 Jan 30;13(2):169-78
references.pmid: 14759363
references.citation: Cancer. 2010 Mar 15;116(6):1419-30
references.pmid: 20120030
references.citation: Blood. 2003 Aug 1;102(3):795-801
references.pmid: 12649163
references.citation: Hematology Am Soc Hematol Educ Program. 2006;:178-84
references.pmid: 17124058
references.citation: Blood. 2009 Oct 1;114(14):2984-92
references.pmid: 19654408
references.citation: Clin Cancer Res. 2003 Nov 15;9(15):5465-76
references.pmid: 14654525
references.citation: Blood. 2005 Jan 1;105(1):54-60
references.pmid: 15345597
references.citation: Leukemia. 2007 Jun;21(6):1224-31
references.pmid: 17377590
references.citation: Oncogene. 2002 Apr 11;21(16):2555-63
references.pmid: 11971190
references.citation: Leuk Lymphoma. 2008 May;49(5):852-63
references.pmid: 18452067
references.citation: N Engl J Med. 2009 Sep 10;361(11):1058-66
references.pmid: 19657110
references.citation: Br J Haematol. 2001 Jun;113(4):983-8
references.pmid: 11442493
references.citation: Leuk Res. 2009 Sep;33(9):1199-203
references.pmid: 19250674
references.citation: Blood. 2007 Nov 15;110(10):3540-6
references.pmid: 17715389
references.citation: Blood. 2004 Jan 15;103(2):479-85
references.pmid: 14512295
references.citation: Blood. 1951 Apr;6(4):372-5
references.pmid: 14820991
references.citation: Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):459-63
references.pmid: 7507245
references.citation: N Engl J Med. 2005 Apr 28;352(17):1779-90
references.pmid: 15858187